Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02480751
Recruitment Status : Completed
First Posted : June 24, 2015
Last Update Posted : June 29, 2015
Astellas Pharma Inc
Information provided by (Responsible Party):
Toray Industries, Inc

Brief Summary:
The purpose of this study is to determine the recommended dose of the sustained-release form of BPS (TRK-100STP low dose or high dose) in Japanese patients with CRF (Primary glomerular disease/nephrosclerosis).

Condition or disease Intervention/treatment Phase
Renal Insufficiency, Chronic Drug: Beraprost Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 113 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : October 2005
Actual Primary Completion Date : May 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1: Exprimental (TRK-100STP)
high dose
Drug: Beraprost
Experimental: 2: Exprimental (TRK-100STP)
low dose
Drug: Beraprost
Placebo Comparator: 3: Placebo Comparator
Drug: Placebo

Primary Outcome Measures :
  1. Difference between the run-in and treatment periods in the slope of the regression line of 1/SCr versus time [ Time Frame: 50 weeks (Run-in 22weeks, Treatment 28 weeks) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease
  • The patient with progressive CRF

Exclusion Criteria:

  • The patient with secondary glomerular disease
  • The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Toray Industries, Inc Identifier: NCT02480751    
Other Study ID Numbers: 100CRS01/533-CL-00
First Posted: June 24, 2015    Key Record Dates
Last Update Posted: June 29, 2015
Last Verified: June 2015
Keywords provided by Toray Industries, Inc:
Chronic Renal Failure
Glomerular Disease; Nephrosclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases
Platelet Aggregation Inhibitors
Vasodilator Agents